Larry C. Heaton II, Chief Executive Officer and Director of Zomedica Corp., filed a statement of changes in beneficial ownership on November 9, 2026, reporting the acquisition of stock options on November 6, 2026.

Key Highlights

  • Reporting person: Larry C. Heaton II, identified as CEO and Director of Zomedica Corp.
  • Transaction date: November 6, 2026, with the filing submitted November 9, 2026.
  • Options acquired: 1,000,000 options to buy Common Stock, acquired (transaction code A) at a price of $0.00.
  • Exercise price: $0.10 per share, with an expiration date of November 5, 2036.
  • Vesting schedule: One quarter of the options vest on the first anniversary of the grant date, then 1/48 vest monthly until fully vested on November 6, 2030.
  • Resulting ownership: 1,000,000 derivative securities beneficially owned following the reported transaction, held directly.

Heaton Option Grant Details and Zomedica Context

According to the filing, Zomedica Corp. is the issuer, with its trading symbol listed as ZOMDF. Larry C. Heaton II, whose address is listed as 1101 Technology Drive, Suite 100, Ann Arbor, Michigan 48108, holds the dual roles of CEO and Director at the company. Zomedica Corp. is an animal health company, and the grant of options to its chief executive reflects a compensation mechanism tied to the company's common stock.

The filing reports that Heaton acquired 1,000,000 options to buy Common Stock at an exercise price of $0.10, with no acquisition cost (price of $0.00 for the derivative security itself). The options carry an expiration date of November 5, 2036, giving a ten-year term from grant. Per the filing's explanation of responses, one quarter of the options are scheduled to vest on the first anniversary of the grant date, with the remaining options vesting at a rate of 1/48 per month thereafter, reaching full vesting on November 6, 2030. No non-derivative securities transactions were reported in Table I of the filing.

The filing was made by one reporting person, signed by Larry Heaton on November 9, 2026. No amendment date was indicated, suggesting this is an original filing. The filing covers only the derivative securities described above, and no indirect ownership or joint filing arrangements were noted.

What Was Disclosed

The filing disclosed that Zomedica Corp. CEO and Director Larry C. Heaton II acquired 1,000,000 stock options at an exercise price of $0.10, expiring November 5, 2036, with a four-year vesting schedule beginning November 6, 2026.